ArticleCureus2022
Sex Differences in COVID-19 Outcomes.
Article in Cureus, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 16 citations in OpenAlex.
- Dissecting Sex-Specific Pathology in K18-hACE2 Transgenic Mice Infected With Different SARS-CoV-2 Variants.Journal of medical virology · 2025Article
- Clinical significance of C-reactive protein in patients with severe fever with thrombocytopenia syndrome.Journal of rural medicine : JRM · 2025Article
- The selective ERβ agonist AC 186 reduces polyinosinic:polycytidylic acid (poly I:C)-induced inflammatory responses in BEAS-2B lung epithelial cells.Frontiers in pharmacology · 2025Article
- A comparative analysis of estrogen receptors, ACE2 and cytokines in pre-and postmenopausal women and men with COVID-19.Frontiers in public health · 2025Article
- Estrogen-dependent gene regulation: Molecular basis of TIMP-1 as a sex-specific biomarker for acute lung injury.Physiological reports · 2024Article
- Regulation of vascular angiotensin II type 1 and type 2 receptor and angiotensin-(1-7)/MasR signaling in normal and hypertensive pregnancy.Biochemical pharmacology · 2024Review
- Safety of Janssen Ad26.COV.S and Astra Zeneca AZD1222 COVID-19 Vaccines among Mobile Phone Users in Malawi: Findings from a National Mobile-Based Syndromic Surveillance Survey, July 2021 to December 2021.International journal of environmental research and public health · 2023Article
- Gender-based research underscores sex differences in biological processes, clinical disorders and pharmacological interventions.Biochemical pharmacology · 2023Review
- COVID-19 is associated with bystander polyclonal autoreactive B cell activation as reflected by a broad autoantibody production, but none is linked to disease severity.Journal of medical virology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified as the cause of an outbreak of severe acute respiratory syndrome in Wuhan City, China in December 2019. Since then, it has caused a worldwide pandemic with over six million deaths. Many studies have been published on coronavirus disease 2019 (COVID-19), but only a few have compared the outcomes of COVID-19 between males and females, especially in African countries and the Middle East. Studies published to date on this topic report that male patients infected with SARS-CoV-2 have worse outcomes than females. This study aimed to compare sex differences in COVID-19 outcomes in a tertiary care hospital in Casablanca (Morocco). Methodology We included all adult patients hospitalized for COVID-19 infection in Cheikh Khalifa Hospital. We categorized patients according to gender and analyzed the characteristics and outcomes of each group. Results In total, 134 patients with polymerase chain reaction (PCR)-confirmed COVID-19 were admitted during the study period. These included 72 (53.7%) men and 62 (46.4%) women. The median age of the patients was 53 years (interquartile range, IQR = 36-64). Men were significantly older than women (58 vs. 44) but there was no significant difference in comorbidities on comparing men and women. Values of median C-reactive protein (35 vs. 4), ferritin (326 vs. 72), and lactate dehydrogenase (264 vs. 208) were significantly higher in men. Lymphopenia was significantly more important in men (1.2 vs. 1.7), and the ratio of neutrophil/lymphocytes was significantly higher in men (3.37 vs. 1.84). Men had greater disease severity, with significantly higher intensive care unit admission (48.6% vs. 16.1%) and higher hospital mortality (18.1% vs. 1.6%). Conclusions COVID-19 gender disparities may be due to sex differences in the inflammatory response. These can be explained by the role of sex hormones and sex chromosomes on immune cells and their regulatory genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.